{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:17:34Z","timestamp":1771226254769,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Kimura disease is a benign chronic inflammatory condition characterized by painless subcutaneous masses, peripheral blood eosinophilia, and increased serum immunoglobulin E levels. The pathogenesis of KD remains unclear, however, more and more evidence suggests that type 2 inflammation may play an important role in KD. We present a case of a 19-year-old male who complained of masses behind both ears for two months, ultimately diagnosed as KD. He showed a partial response to the initial systemic corticosteroid therapy. However, after tapering the dosage of corticosteroids, the patient\u2019s symptoms did not improve, even with combined mycophenolate mofetil therapy. His symptoms worsened significantly after he discontinued treatment. Therefore, treatment with dupilumab was initiated at 600 mg, followed by 300 mg every two weeks. At week 20, the treatment was adjusted to 300 mg every four weeks for a duration of 32 weeks. The mass gradually reduced in size, accompanied by a progressive decrease in both the eosinophil count and IgE levels. These results show the significant efficacy of dupilumab in the management of KD.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1670489","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:36:05Z","timestamp":1771223765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Kimura disease with dupilumab: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111895","article-title":"Kimura\u2019s disease treated with dupilumab: A case report and literature review","volume":"131","author":"Luo","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01711.x","article-title":"Kimura disease: review of the literature","volume":"38","author":"Sun Q","year":"2008","journal-title":"Internal Med J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121810","article-title":"A rare kimura\u2019s disease in the oral cavity with severe sleep apnea: case report and literature review","volume":"58","author":"Lei","year":"2022","journal-title":"Medicina"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7181\/acfs.2022.01053","article-title":"Current concepts of Kimura disease: pathophysiology and evolution of treatment","volume":"23","author":"Kim","year":"2022","journal-title":"Arch Craniofac Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.04.010","article-title":"Treatment of Kimura disease with mycophenolate mofetil monotherapy","volume":"3","author":"Shah","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb01562.x","article-title":"In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporin A in a patient with Kimura\u2019s disease","volume":"137","author":"Katagiri","year":"1997","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000003106","article-title":"Kimura disease of the thigh treated with surgical excision and dupilumab","volume":"88","author":"Huang","year":"2022","journal-title":"Ann Plast Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.anl.2010.03.011","article-title":"Increase of Th2 and Tc1 cells in patients with Kimura\u2019s disease","volume":"38","author":"Ohta","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2002.01552.x","article-title":"Mast cells and T cells in Kimura\u2019s disease express increased levels of interleukin-4, interleukin-5, eotaxin and RANTES","volume":"32","author":"Kimura","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3730","article-title":"Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells","volume":"90","author":"Punnonen","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaci.2022.03.034","article-title":"Distinct disease-specific Tfh cell populations in 2 different fibrotic diseases: IgG4-related disease and Kimura disease","volume":"150","author":"Munemura","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5885","article-title":"Treatment of kimura disease with dupilumab","volume":"158","author":"Teraki","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(85)70098-9","article-title":"Angiolymphoid hyperplasia with eosinophilia. A clinicopathologic study of 116 patients","volume":"12","author":"Olsen","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2732","article-title":"Role of eosinophils in angiolymphoid hyperplasia with eosinophilia","volume":"157","author":"Gr\u00fcnewald","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106591","article-title":"Treatment algorithm for Kimura\u2019s disease: A systematic review and meta-analysis of treatment modalities and prognostic predictors","volume":"100","author":"Lee","year":"2022","journal-title":"Int J Surg"},{"key":"B16","article-title":"Radiotherapy for Kimura\u2019s disease: case report and review of the literature","volume":"12","author":"Kilciksiz","year":"2007","journal-title":"J BUON"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1084","DOI":"10.1002\/iid3.1084","article-title":"Clinical effects of dupilumab: A novel treatment for Kimura disease","volume":"11","author":"Shang","year":"2023","journal-title":"Immun Inflam Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e34191","DOI":"10.1097\/MD.0000000000034191","article-title":"Diagnostic challenges and updated therapeutic strategies of Kimura\u2019s disease: A case report successfully treated by dupilumab and review","volume":"102","author":"Cordeil","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492547","article-title":"Dupilumab combined with corticosteroid therapy for Kimura disease with multiple systemic masses: a case report and literature review","volume":"15","author":"Lyu","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15674","article-title":"Dupilumab for recalcitrant Kimura disease","volume":"35","author":"Bellinato","year":"2022","journal-title":"Dermatologic Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae048","article-title":"Efficacy and safety of dupilumab in the treatment of Kimura\u2019s disease","volume":"117","author":"Liu","year":"2024","journal-title":"QJM"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.06.002","article-title":"Single-cell RNA sequencing of peripheral blood mononuclear cells from Kimura disease patient successfully treated with dupilumab","volume":"72","author":"Suga","year":"2023","journal-title":"Allergol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad455","article-title":"Two cases of dupilumab-responsive Kimura disease","volume":"49","author":"Battesti","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2449153","article-title":"Successful treatment of Kimura\u2019s disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses","volume":"36","author":"Zheng","year":"2025","journal-title":"J Dermatol Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13084","article-title":"The use of omalizumab in allergen immunotherapy","volume":"48","author":"Dantzer","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2013.12.006","article-title":"Anti-IgE therapy to Kimura\u2019s disease: a pilot study","volume":"41","author":"Nonaka","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1084879","article-title":"Successful treatment of dupilumab in Kimura disease independent of IgE: A case report with literature review","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.049","article-title":"Mepolizumab-responsive kimura disease","volume":"9","author":"Kinoshita","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04873-0","article-title":"Successful treatment of Kimura disease with benralizumab","volume":"101","author":"Szeto","year":"2022","journal-title":"Ann Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3181acedf8","article-title":"Concomitant occurrence of kimura disease and mycosis fungoides in a Lebanese woman: significance and response to rituximab","volume":"31","author":"Ghosn","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-023-00778-7","article-title":"A case of minimal change nephrotic syndrome complicated by Kimura disease treated with rituximab","volume":"12","author":"Yoshida","year":"2023","journal-title":"CEN Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1670489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:36:06Z","timestamp":1771223766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1670489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1670489"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1670489","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"1670489"}}